2-甲基-2-丙基[5-(氨基甲基)-2-吡嗪基]氨基甲酸酯 | 369638-71-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-甲基-2-丙基[5-(氨基甲基)-2-吡嗪基]氨基甲酸酯
• 英文名称: tert-butyl N-[5-(aminomethyl)pyrazin-2-yl]carbamate
• CAS: 369638-71-1
• 化学式: C₁₀H₁₆N₄O₂
• 分子量: 224.263
• InChiKey: RPXRWQLSUYIKRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  315.4±42.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  90.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基[5-(氨基甲基)-2-吡嗪基]氨基甲酸酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 生成 N-(5-Amino-pyrazin-2-ylmethyl)-2-[3-(2,2-difluoro-2-phenyl-ethylamino)-6-methyl-2-oxo-2H-pyrazin-1-yl]-acetamide
  参考文献：
  名称：

  Non-covalent thrombin inhibitors featuring p 3 -heterocycles with P 1 -monocyclic arginine surrogates

  摘要：

  Investigations on P-2-P-3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P-1-arginine derivatives. The design. synthesis. and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P-1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydrox amidines, (2) 2-aminopyrazines. and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00129-4
• 作为产物：
  描述：

  (5-溴乙基吡嗪-2-基)氨基甲酸叔丁酯 在 palladium on activated charcoal sodium azide 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 5.0h， 生成 2-甲基-2-丙基[5-(氨基甲基)-2-吡嗪基]氨基甲酸酯
  参考文献：
  名称：

  Non-covalent thrombin inhibitors featuring p 3 -heterocycles with P 1 -monocyclic arginine surrogates

  摘要：

  Investigations on P-2-P-3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P-1-arginine derivatives. The design. synthesis. and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P-1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydrox amidines, (2) 2-aminopyrazines. and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00129-4

文献信息

• [EN] PYRAZINONE AND PYRIDINONE DERIVATIVES AS THROMBIN INHIBITORS<br/>[FR] INHIBITEURS DE LA THROMBINE A BASE DE DERIVES DE PYRAZINONE ET PYRIDINONE
  申请人：CORVAS INT INC

  公开号：WO2001079262A1

  公开（公告）日：2001-10-25

  The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and which feature a six member heterocyclic ring having two ring nitrogen atoms and the remainder of the ring atoms carbon atoms at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.
• Non-covalent thrombin inhibitors featuring p 3 -heterocycles with P 1 -monocyclic arginine surrogates
  作者：John E Reiner、Daniel V Siev、Gian-Luca Araldi、Jingrong Jean Cui、Jonathan Z Ho、Komandla Malla Reddy、Lala Mamedova、Phong H Vu、Kuen-Shan S Lee、Nathaniel K Minami、Tony S Gibson、Susanne M Anderson、Annette E Bradbury、Thomas G Nolan、J.Edward Semple

  DOI：10.1016/s0960-894x(02)00129-4

  日期：2002.4

  Investigations on P-2-P-3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P-1-arginine derivatives. The design. synthesis. and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P-1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydrox amidines, (2) 2-aminopyrazines. and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines. (C) 2002 Elsevier Science Ltd. All rights reserved.